AD Therapeutic Landscape

Last refreshed: 2026-06-11T19:38:38.989446+00:00
Industry
Academia
Consortia
|
SciDEX score (low→high)
Bar = sponsor mix per cell

Mechanism Score (SciDEX hypotheses)

Open Frontiers — top gaps

  • 0.85 Ferroptosis in ALS and Motor Neuron Disease: GPX4, Lipid Peroxidation, and Iron Chelation Therapies (neurodegeneration)
  • 0.85 Extracellular vesicle biomarkers for early AD detection (neurodegeneration)
  • 0.72 Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidirectional relationship between sleep disorders (particularly circadian (neurodegeneration)
  • 0.72 Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data) (neurodegeneration)
  • 0.72 Is C1q elevation in human AD causally pathogenic or an epiphenomenon of neuroinflammation? (neurodegeneration)